This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD); schizophrenia	Serotonin (5-HT ₆) receptor	<p><i>In vitro</i> and rat studies suggest that a class of 5-HT₆ receptor antagonists could help treat cognitive impairment in AD and schizophrenia. <i>In vitro</i>, piperazinyl-sulfonylindazole analogs were selective low nanomolar antagonists of the 5-HT₆ receptor. In a rat model of chemically induced memory deficit, the lead analog improved memory retention better than vehicle. Future studies could include optimization to improve pharmacokinetics and brain penetration of the lead compound.</p> <p>Lu AE58054, a 5-HT₆ receptor antagonist from H. Lundbeck A/S, has completed Phase II testing to treat schizophrenia and is in Phase II testing to treat AD. AVN-211, a small molecule 5-HT₆ receptor antagonist from Avineuro Pharmaceuticals Inc., is in Phase II testing to treat schizophrenia. SB-742457 (742457), a 5-HT₆ receptor antagonist from GlaxoSmithKline plc, is in Phase II testing to treat mild-to-moderate AD.</p> <p>SciBX 3(42); doi:10.1038/scibx.2010.1273 Published online Oct. 28, 2010</p>	Patent and licensing status unavailable	<p>Liu, K.G. <i>et al. J. Med. Chem.</i>; published online Oct. 8, 2010; doi:10.1021/jm1007825</p> <p>Contact: Kevin G. Liu, Lundbeck Research, Paramus, N.J. e-mail: liuk@lundbeck.com</p> <p>Contact: Albert J. Robichaud, same affiliation as above e-mail: ajr@lundbeck.com</p>